Table 1

Baseline demographics and disease characteristics

GlargineBIL
n159307
Age (years), mean ± SD60.4 ± 10.161.8 ± 8.5
Men, n (%)93 (58.5)175 (57.0)
Race/ethnicity, n (%)
 American Indian or Alaskan Native0 (0.0)2 (0.7)
 Asian2 (1.3)4 (1.3)
 Black or African American9 (5.7)17 (5.6)
 Multiple0 (0.0)1 (0.3)
 Native Hawaiian or other Pacific Islander0 (0.0)1 (0.3)
 White148 (93.1)280 (91.8)
 Hispanic or Latino25 (15.7)57 (18.6)
Weight (kg), mean ± SD91.8 ± 18.592.2 ± 17.1
BMI (kg/m2), mean ± SD31.9 ± 5.032.1 ± 5.0
Duration of diabetes (years), mean ± SD12.1 ± 6.812.4 ± 6.9
Baseline insulin use, n (%)
 Insulin glargine119 (74.8)218 (71.0)
 Insulin detemir25 (15.7)65 (21.2)
 NPH insulin15 (9.4)24 (7.8)
OAMs at or prior to randomization, n (%)
 Metformin140 (88.1)270 (88.5)
 Sulfonylureas or meglitinides74 (46.5)144 (46.9)
 Dipeptidyl peptidase-4 inhibitors34 (21.4)76 (24.9)
 Thiazolidinediones7 (4.4)19 (6.2)
OAM use during treatment, n (%)
 None8 (5.0)16 (5.2)
 One57 (35.8)108 (35.4)
 Two83 (52.2)141 (46.2)
 Three11 (6.9)40 (13.1)
Patients using concomitant medications, n (%)
 Lipid-lowering medications109 (68.9)213 (69.4)
 Statins103 (64.8)195 (63.5)
 Nonstatin lipid-lowering medications24 (15.1)63 (20.5)
HbA1c ≤8.0% (64 mmol/mol), n (%)125 (78.6)243 (79.2)
Hypertension, n (%)133 (83.6)264 (86.0)